Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-24 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Diamyd Medical - Carnegie Investment Bank - 24 april 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-04-24 | Penser Access by Carnegie | Penser Access by Carnegie: Diamyd Medical - Går en spännande framtid till mötes | Pressreleaser | Visa Stäng |
|
||||
2024-04-18 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces final outcome in the company's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-18 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör slutgiltigt utfall i bolagets företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör preliminärt utfall i bolagets företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces preliminary outcome in the company's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-12 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Diamyd Medical - Carnegie Investment Bank - 12 april 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-04-12 | Diamyd Medical | Diamyd Medical AB: Rekryteringsmilstolpe har uppnåtts i fas III-studie med Diamyd® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-12 | Diamyd Medical | Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Diamyd Medical | Diamyd Medical AB: Innovationsmiljön ASSET, lett av Diamyd Medical, håller en workshop om framtidens behandling av typ 1-diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-05 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-05 | Diamyd Medical | Diamyd Medical AB: Diamyd Medicals storägare meddelar teckningsåtagande i pågående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-02 | Penser Access by Carnegie | Penser Access by Carnegie: Diamyd Medical - Fyller på kassan | Pressreleaser | Visa Stäng |
|
||||
2024-03-28 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör prospekt avseende företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Diamyd Medical | Diamyd Medical AB: Delårsrapport II 23/24 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Diamyd Medical | Diamyd Medical AB: Quarterly Report II 23/24 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-18 | Diamyd Medical | Diamyd Medical AB: Styrelsen i Diamyd Medical har beslutat om en företrädesemission om cirka 114 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-18 | Diamyd Medical | Diamyd Medical AB: The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical presenterar nya genetiska data på ASIT Summit i Boston | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Diamyd Medical - Carnegie Investment Bank - 22 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-15 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-15 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical erhåller Fast Track designation för Diamyd® av den amerikanska läkemedelsmyndigheten FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-14 | Diamyd Medical | Diamyd Medical AB: Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-14 | Diamyd Medical | Diamyd Medical AB: Publikation i Diabetologia belyser AI:s potential för screening av typ 1-diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Diamyd Medical - Carnegie Investment Bank - 30 jan 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-01-26 | Penser Access by Carnegie | Penser Access by Carnegie: Diamyd Medical - Alla ögon på DIAGNODE-3 | Pressreleaser | Visa Stäng |
|
||||
2024-01-24 | Diamyd Medical | Diamyd Medical AB: In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Diamyd Medical | Diamyd Medical AB: Fördjupad analys av Fas II-studie med Diamyd® stöder ytterligare värdet av bevarad insulinproduktion | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Diamyd Medical | Diamyd Medical AB: Quarterly Report I 23/24 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Diamyd Medical | Diamyd Medical AB: Delårsrapport I 23/24 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-08 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical gains market research findings to guide U.S. commercial strategy | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-08 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical informerar om marknadsanalys inför kommersiell strategi i USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-04 | Diamyd Medical | Diamyd Medical AB: Interimsanalys av precisionsmedicinsk fas 3-studie med Diamyd® i juli | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-04 | Diamyd Medical | Diamyd Medical AB: Diamyd® precision medicine Phase 3 trial key interim analysis in July | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-06 | Diamyd Medical | Diamyd Medical AB: Diamyd Medicals precisionsmedicinska patent för förebyggande och behandling av autoimmun diabetes beviljat i Sydkorea | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-06 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical's Precision Medicine patent for the prevention and treatment of autoimmune diabetes granted in South Korea | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Diamyd Medical | Bulletin from Annual General Meeting of Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Diamyd Medical | Kommuniké från årsstämma i Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Diamyd Medical | Diamyd Medical AB: Annual Report 2022/2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-13 | Penser Access | Penser Access: Intervju med Diamyd Medical - Erik Penser Bank - 13 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-09 | Penser Access | Penser Access: Kassan påfylld - Diamyd Medical | Pressreleaser | Visa Stäng |
|
||||
2023-11-09 | Diamyd Medical | Diamyd Medical AB: Årsredovisning 2022/2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Diamyd Medical | Diamyd Medical AB: Information om årsredovisning 2022/23 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Diamyd Medical | Diamyd Medical AB: Information about the Annual Report 2022/23 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-07 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical ingår samarbete med DiaUnion för rekrytering till typ 1-diabetes-preventionsstudie | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-07 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical partners with DiaUnion to recruit participants for Type 1 diabetes prevention trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-01 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces final outcome in the company's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-01 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör slutgiltigt utfall i bolagets företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör preliminärt utfall i bolagets företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces preliminary outcome in the company's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Diamyd Medical | Kallelse till årsstämma i Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör tilläggsprospekt avseende företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Diamyd Medical | Diamyd Medical AB: Uppföljningsstudie tyder på att Diamyd® kan ge fördelar vad gäller att fördröja typ 1-diabetesdiagnos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Diamyd Medical | Diamyd Medical AB: Follow-up study suggests Diamyd® may offer advantages in delaying type 1 diabetes onset | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Diamyd Medical | Diamyd Medical AB: BioStock: Diamyd Medical om fas III-studien och emissionen | Pressreleaser | Visa Stäng |
|
||||
2023-10-24 | Diamyd Medical | Diamyd Medical AB: BioStock: Emission ska ta Diamyd Medical genom fas III | Pressreleaser | Visa Stäng |
|
||||
2023-10-20 | Diamyd Medical | Diamyd Medical AB: Preliminary results from Booster trial with Diamyd® provide additional support for intralymphatic injections | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-20 | Diamyd Medical | Diamyd Medical AB: Preliminära resultat från booster-studie med Diamyd® ger ytterligare stöd för intralymfatiska injektioner | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Diamyd Medical | Diamyd Medical AB: BioStock Investor Pitch: Diamyd Medical | Pressreleaser | Visa Stäng |
|
||||
2023-10-18 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-10-17 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces a webcast presentation on October 20 regarding its industry partnership with JDRF | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-17 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical håller en webbsänd presentation den 20 oktober om branschpartnerskapet med JDRF | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-17 | Diamyd Medical | Diamyd Medical AB: BioStock: Diamyd Medicals vd om företrädesemissionen | Pressreleaser | Visa Stäng |
|
||||
2023-10-16 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-16 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör prospekt avseende företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-12 | Penser Access | Penser Access: Genomför företrädesemission - Diamyd Medical | Pressreleaser | Visa Stäng |
|
||||
2023-10-11 | Diamyd Medical | Diamyd Medical AB: Year-End Report 22/23 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Diamyd Medical | Diamyd Medical AB: Bokslutskommuniké 22/23 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-10 | Diamyd Medical | Bulletin from Extra General Meeting of Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-10 | Diamyd Medical | Kommuniké från extra bolagsstämma i Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Diamyd Medical | Diamyd Medical AB: Anders Essen-Möller utsedd till styrelseordförande i Diamyd Medical | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Diamyd Medical | Diamyd Medical AB: Anders Essen-Möller has been appointed Chairman of the Board of Diamyd Medical | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-25 | Penser Access | Penser Access: Intervju med Diamyd Medical - Erik Penser Bank - 25 september 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-09-21 | Diamyd Medical | Kallelse till extra bolagsstämma i Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-20 | Diamyd Medical | Diamyd Medical AB: The Board of Directors in Diamyd Medical resolves on a rights issue of approximately SEK 243 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-20 | Diamyd Medical | Diamyd Medical AB: Styrelsen i Diamyd Medical beslutar om en företrädesemission om cirka 243 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-05 | Diamyd Medical | Diamyd Medical AB: Registreringsgrundande fas III-studie i typ 1-diabetes med Diamyd® expanderar till USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-05 | Diamyd Medical | Diamyd Medical AB: Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-16 | Diamyd Medical | Diamyd Medical AB: Resultaten från antigenspecifik immunoterapi i LADA med Diamyd® publicerade i vetenskaplig tidskrift | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-16 | Diamyd Medical | Diamyd Medical AB: Results from Diamyd® Antigen-Specific Immunotherapy Trial in LADA published in scientific journal | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Penser Access | Penser Access: Klirr i kassan - Diamyd Medical | Pressreleaser | Visa Stäng |
|
||||
2023-06-28 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces final outcome in the company's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör slutgiltigt utfall i bolagets företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Diamyd Medical | Diamyd Medical AB: Quarterly Report III 22/23 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Diamyd Medical | Diamyd Medical AB: Delårsrapport III 22/23 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-27 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör preliminärt utfall i bolagets företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-27 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical announces preliminary outcome in the company's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-26 | Diamyd Medical | Bulletin from Extra General Meeting of Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-26 | Diamyd Medical | Kommuniké från extra bolagsstämma i Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-19 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical's largest owner fully subscribes for his share in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-19 | Diamyd Medical | Diamyd Medical AB: Diamyd Medicals största ägare tecknar sin andel i pågående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-14 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör tilläggsprospekt avseende företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical avstår från att göra gällande emissionsgarantiavtalen i företrädesemissionen och förlänger teckningsperioden | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical refrains from enforcing the underwriting agreements in the rights issue and extends the subscription period | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical provides an update regarding the ongoing new share issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical ger en uppdatering avseende den pågående nyemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-05 | Diamyd Medical | Diamyd Medical AB: Trading in subscription rights in Diamyd Medical's rights issue halted | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-05 | Diamyd Medical | Diamyd Medical AB: Handeln i teckningsrätter i Diamyd Medicals nyemission stoppad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-05 | Diamyd Medical | Diamyd Medical AB: Handeln i teckningsrätter i Diamyd Medicals företrädesemission inleds i dag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-01 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical provides supplementary information about the upcoming Extraordinary General Meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-01 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical lämnar kompletterande information om den kommande extra bolagsstämman | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-01 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical offentliggör prospekt avseende företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Diamyd Medical | Kallelse till extra bolagsstämma i Diamyd Medical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical beslutar om en företrädesemission av aktier om cirka 163 MSEK och kallar till extra bolagsstämma för beslut om emission av teckningsoptioner och ändring av bolagsordningen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Diamyd Medical | Diamyd Medical AB: Diamyd Medical resolves on a rights issue of shares of approximately SEK 163 million and convenes an EGM to resolve on an issue of warrants and amendment of the articles of association | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Diamyd Medical AB: Diamyd Medical resolves on a rights issue of shares of approximately SEK 163 million and convenes an EGM to resolve on an issue of warrants and amendment of the articles of associationSummary of the Rights Issue
Summary of the issue of warrants and the EGM
It should be noted that the structure of the Rights Issue is intended to be identical to if Diamyd would carry out the Rights Issue as an issue of units, where each unit consists of two B-shares, one warrant of series TO3 and one warrant of series TO4. The reason why Diamyd Medical does not carry out the Rights Issue with units is that the Board of Directors’ authorization does not include warrants and that the articles of association must be amended to accommodate the shares that may be issued as a result of the exercise of warrants. Background and reason The registration-based, precision medicine phase 3 trial DIAGNODE-3 with Diamyd[®] for the treatment of newly diagnosed type 1 diabetes in children and young adults, who carry a certain gene associated with positive treatment outcome in previous trials, is ongoing in eight countries in Europe and set to start in the US later in 2023. The trital is the last step before potential market approval. With the FDA’s approval of the start of the trial for DIAGNODE-3 in November 2022, about a dozen American clinics will be added to the approximately 50 clinics already activated in Europe. DIAGNODE-3 will enroll approximately 330 patients aged 12-29 years who has been newly diagnosed with type 1 diabetes and carrying the specific genotype in which Diamyd[®] in previous trials has shown efficacy towards. The trial design has been established in cooperation with the US and European pharmaceutical authorities FDA and EMA, and is supported by robust results from previous clinical trials with over 1,000 patients. All the results on which the phase 3 trial is based, are published in renowned peer-reviewed scientific journals. Together with a strong IP protection and market exclusivity upon market approval in the form of orphan drug designation in the US, and market exclusivity as a biological drug for 12 and 10 years respectively in the US and Europe, the Company’s assessment is that the conditions, upon market approval, to quickly penetrate a large part of the market that the Company targets are very promising. The purpose of the Rights Issue is to finance the DIAGNODE-3 trial, construction of the Company’s production facility for biological products as well as the ongoing operations at least until the end of 2024, including preparatory activities for the planned commercialization of Diamyd[®] starting in 2027 if market approval in the US and Europe is obtained. Use of issue proceeds
Preliminary timeline for the Rights Issue May 29, 2023 Last day of trading in B-shares The above preliminary timeline is conditional on that the Prospectus is approved and can be published at the estimated time, i.e. June 1, 2023. Subscription commitments and guarantee commitments In addition to the aforementioned subscription commitments, external guarantors have provided guarantee commitments subject to customary conditions which, in aggregate, amount to approximately SEK 115.2 million, corresponding to approximately 70.5 percent of the Rights Issue. Consequently, the Rights Issue is covered by subscription commitments and a guarantee consortium, syndicated by G&W Fondkommission, amounting to approximately SEK 116 million, corresponding to approximately 71 percent of the Rights Issue. For the guarantees, a guarantee fee of fourteen (14) percent of the guaranteed and allotted amount is paid, of which ten (10) percent will be paid in cash and four (4) percent is to be offset against newly issued B-shares. The part of the guarantee fee which is to be paid in newly issued B-shares is to be effectuated by a directed issue, resolved by the Board of Directors pursuant to the authorization granted by the annual general meeting on December 1, 2022. The guarantee fee is based on current market conditions. No fee is to be paid for the subscription commitments that have been entered into. Neither the subscription commitments nor the guarantee commitments are secured through pledged assets, restricted funds or similar arrangements. Further information regarding the parties who have entered into subscription commitments and guarantee commitments will be presented in the Prospectus, which, in accordance with the preliminary timetable, is expected to be published on June 1, 2023. Overallotment option Change of number of shares and share capital Shareholders who choose not to subscribe in the Rights Issue may therefore be faced with a maximum dilution effect of approximately 20 percent, calculated as new shares divided by the total number of outstanding shares after the Rights Issue, but are given the opportunity to be financially compensated for this dilution effect by selling their received subscription rights. In addition, there is a dilution of approximately 0.5 percent of the number of shares and votes as a result of the part of the guarantee fee which is to be paid for in newly issued B-shares. If the Board of Directors of Diamyd Medical resolves on the overallotment option, shareholders will be faced with a dilution effect of an additional maximum of approximately 2.4 percent of the number of shares and votes. Shareholders who choose not to subscribe in the Rights Issue can therefore at most be faced with a dilution effect corresponding to approximately 22.3 percent of the number of shares and votes. Upon full subscription in the Rights Issue, execution of the directed issue for payment of guarantee fee and that the overallotment option is exercised to the highest possible amount, Diamyd Medical’s share capital will thereby increase by SEK 2,224,127.1179 from SEK 7,802,027.0588 to SEK 10,046,154.1767 and the number of shares by 22,126,792 from 76,926,939 shares to 99,053,731 shares, meaning that the number of A-shares after the Rights Issue amounts to 2,556,223 A-shares and the number of B-shares increases from 74,370,716 B-shares to 96,497,508 B-shares. Prospectus Advisors About Diamyd Medical Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser. |
||||
2023-05-15 | Penser Access | Penser Access: Intervju med Diamyd Medical - Erik Penser Bank - 15 maj 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-11 | Penser Access | Penser Access: Storm i ett vattenglas - Diamyd Medical | Pressreleaser | Visa Stäng |
|
||||
2023-05-10 | Diamyd Medical | Diamyd Medical AB: Topline-resultat från Remygen®-studie i individer med långvarig typ 1-diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Diamyd Medical | Diamyd Medical AB: Topline results from Remygen® trial in individuals with long-term Type 1 Diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|